Physician profile
Jason H Brajer
NPI 1609856723
$6,125.67
in general payments reported to CMS, 2019-2025
31 companies · $1,326 in 2025
The $1,326 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $611 · 2020: $479 · 2021: $563 · 2022: $879 · 2023: $1,155 · 2024: $1,113 · 2025: $1,326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,593.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,593.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $885.50 | 2020-2023 | Proclaim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $685.56 | 2023-2025 | Relistor, Xifaxan, Trulance |
| Abbvie INC. | $680.84 | 2021-2025 | Vraylar, Botox, Ubrelvy |
| Medtronic, INC. | $619.96 | 2021-2025 | Synchromedii |
| Collegium Pharmaceutical, INC. | $570.79 | 2019-2025 | Belbuca, Xtampza |
| Nevro Corp. | $507.47 | 2019-2020 | |
| Foundation Fusion Solutions, LLC | $465.42 | 2022-2025 | |
| Spr Therapeutics, INC | $319.81 | 2019-2025 | Sprint Pns System |
| Teva Pharmaceuticals USA, INC. | $182.83 | 2019-2025 | Austedo, Austedo Xr |
| Medtronic USA, INC. | $181.10 | 2019-2020 | |
| Averitas Pharma INC. | $147.18 | 2023-2025 | Qutenza |
| Vertos Medical, INC. | $142.86 | 2019 | |
| Relievant Medsystems, INC. | $84.64 | 2019 | |
| Si-Bone, INC. | $79.68 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $62.67 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $61.47 | 2022-2023 | Mounjaro |
| Pfizer INC. | $60.89 | 2023-2024 | |
| Bioventus LLC | $60.81 | 2024-2025 | Durolane, Xcell |
| Grt US Holding, INC. | $49.58 | 2022 | |
| Zimmer Biomet Holdings, INC. | $49.02 | 2024 | Gel-One Cross-Linked Hyaluronate |
| Vertex Pharmaceuticals Incorporated | $36.73 | 2024-2025 | |
| Biodelivery Sciences International, INC. | $29.41 | 2021 | |
| Ibsa Pharma INC. | $29.32 | 2021-2022 | |
| Boston Scientific Corporation | $21.50 | 2023 | Wavewriter Alpha Prime 16 |
| Tersera Therapeutics LLC | $19.24 | 2023 | Prialt |
| Appliedvr INC | $18.56 | 2025 | Relievrx |
| Avanos Medical | $18.26 | 2022 | |
| International Rehabilitative Sciences, INC | $14.89 | 2025 | Rs-4i Plus With Intersperse |
| Biohaven Pharmaceuticals, INC. | $14.11 | 2021 | |
| Prescient Lab Services, LLC | $13.47 | 2025 | Avertd Biofilmchip Microarray Magazine, Avertd Intellipac Reagent Module, Avertd Amplification Mix |
| Forte Bio-Pharma LLC | $12.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Brajer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.